Migraine Drugs Market Research Report - Global Forecast till 2027

Global Migraine Drugs Market Research Report: By Type (Episodic Migraine, Chronic Migraine), By Treatment Type (Acute, Preventive, Neuromodulation Devices), By Drug Class (Triptans, Betablockers, Angiotensin Blockers, Tricyclics, Anticonvulsants) and By End-User (Hospitals and Clinics, Retail Pharmacy, Online Pharmacy, Others) – Forecast to 2027

ID: MRFR/HC/6907-HCR | February, 2021 | Region : Global

Market Forecast


Global Migraine Drugs Market is expected to hold a value of USD 6.5 Billion by 2025 at a CAGR of 5.9%.


Migraine Drugs Market Synopsis


Migraine is a common neurovascular sickness that is characterized by tender headaches and is commonly associated with other neurological indications, such as nausea, vomiting, and painful sensitivity to lights and sounds. Migraine is more common in women than men, majorly due to the fluctuations in hormone levels. As of 2018, approximately 14.5% world’s population was suffering from different types of migraines, and 2% of the world’s population was suffering from chronic migraines.  


The treatment of migraine headaches is eased by the administration of preventive medications, to avoid the migraine attacks and abortive medications to relieve the strong and periodic pain.


Migraine Drugs Market Influencer


The increasing prevalence of migraine is expected to contribute to the growth of the migraine drugs market during the forecast period.


Market Drivers



  • Increasing prevalence of migraine worldwide. As of January 2019, 2.9% of the deaths occurred due to migraine worldwide.

  • Rapidly changing lifestyle

  • Growing awareness programs regarding the prevention and treatment of migraine

  • Rising R&D investment for the development of innovative drugs for the treatment of migraine

  • Increased uptake of novel drug classes and the introduction of peptide-based therapies for the treatment of migraine


Market Restraints



  • Stringent government regulations

  • High investment required for drug research and development

  • Side-effects of medications prescribed for migraine


Global Migraine Drugs Market Segmentation


By Type



  • Episodic Migraine: It is characterized by patients with migraine who have 0 to 14 headache days per month. This segment holds the highest share in the market.

  • Chronic Migraine: It is characterized by patients with migraine who have 15 or more headache days per month. This segment is expected to grow faster during the forecast period. Chronic migraine affected approximately 2% of the global population.


By Treatment type



  • Acute: It is the largest segment. It represents approximately 90% of the share in the market. This segment is expected to register a CAGR of 6.1% during the forecast period. All the patients suffering from migraine require acute therapy, regardless of whether they are also treated with preventative therapy. In addition to this, acute treatments are also used in combination with preventive treatments. Major companies in the market are conducting R&D of novel acute therapeutics, and it is expected that 5 to 8 major drugs will be launched that will boost the market during the forecast period.

  • Preventive: It is the second-largest segment in the market. It holds 8% share in the market. Preventative treatments reduce frequency and disability of migraine. The major drugs classes included in preventive treatments are beta-blockers, botulin toxins, and topiramate.

  • Neuromodulation Devices: It is the fastest segment in the market. It holds approximately 2% share in the market. There are three major FDA approved neuromodulation devices for the treatment of migraine in the US market.  


By Drug Class



  • Triptans: It holds the highest share in the market. It is used in the acute treatment of migraine.

  • Betablockers: These are majorly used in the preventive migraine therapeutics.

  • Angiotensin Blockers: These are used as preventive headache treatments for chronic migraine.

  • Tricyclics: These are used as preventive headache treatments for chronic migraine. Tricyclic antidepressants (TCAs) are the first agents shown to be effective in the prophylaxis of migraine.

  • Anticonvulsants: These drugs prevent seizures, headaches, and acute migraines. Topiramate (Qudexy XR, Topamax) and valproic acid (Depakene, Depakote) anticonvulsants are used for the treatment of acute migraine


By End-User



  • Hospitals and Clinics: The largest segment. Hospitals and clinics are the primary points of care for the treatment of migraine. Rising prevalence of migraine is expected to drive the market growth.

  • Retail Pharmacy: It is the second largest segment and provides prescribed migraine drugs for chronic migraine conditions and over the counter migraine drugs for acute migraine conditions.

  • Online Pharmacy: It is the fastest-growing segment which provides migraine drugs through e-commerce platforms. The drug class majorly offered by online pharmacy chains are for acute migraine treatment

  • Others: This segment includes centers for home care and elderly population.


By Region



  • Americas: The largest regional market. The prevalence of migraine is high in the Americas. Approximately, 12% of the US population including 18% of women, 6% of men, and 10% of the children were suffering from different types of migraines in the US as of December 2018. Moreover, the healthcare infrastructure in the Americas is also developed, which contributes to market growth. Furthermore, major pharmaceutical companies such as Pfizer Inc. and Alder Biopharmaceuticals, Inc. are headquartered in the US, which positively contributes to the growth of the migraine drugs market in the Americas.



  • Europe: An increasing prevalence of neurological diseases including migraine in major countries such as the UK, Germany, France, Italy, Spain, and Russia, increasing healthcare expenditure, availability of funds for research, and rising R&D investment for the development of innovative drugs for migraine are anticipated to drive the market growth in Europe. Approximately 1 in 7 people in the UK experience migraine. It also stated that there are around 190,000 migraine attacks in the UK as of December 2018.



  • Asia-Pacific: The fastest-growing regional market. Asia-Pacific is seeing a surge in the number of people suffering from migraine. Moreover, government and non-government organizations are conducting awareness programs for migraine, which is expected to drive the market growth.



  • Middle East & Africa: The market is expected to show significant growth due to the rising patient population suffering from migraine. The market in the Middle East is expected to show more growth as compared to the African market owing to fast-developing healthcare facilities in the Middle Eastern countries such as Saudi Arabia, Qatar, and Oman.


Migraine Drugs Market Key Players



  • Allergan Plc (Ireland)

  • Alder Biopharmaceuticals, Inc. (US)

  • Pfizer Inc. (US)

  • GlaxoSmithKline Plc (UK)

  • Merck & Co., Inc. (US)

  • Teva Pharmaceutical Industries Ltd (Israel)

  • AstraZeneca PLC (UK)

  • Johnson & Johnson Services, Inc. (US)

  • Amgen Inc. (US)

  • Eli Lilly and Company

  • eNeura Inc.

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

6. GLOBAL MIGRAINE DRUGS MARKET, BY TYPE

6.1. Overview

6.2. Episodic Migraine

6.2.1. Market Estimates & Forecast, by Region, 2020-2027

6.2.2. Market Estimates & Forecast, by Country, 2020-2027

6.3. Chronic Migraine

6.3.1. Market Estimates & Forecast, by Region, 2020-2027

6.3.2. Market Estimates & Forecast, by Country, 2020-2027

7. GLOBAL MIGRAINE DRUGS MARKET, BY TREATMENT TYPE

7.1. Overview

7.2. Acute

7.2.1. Market Estimates & Forecast, by Region, 2020-2027

7.2.2. Market Estimates & Forecast, by Country, 2020-2027

7.3. Preventive

7.3.1. Market Estimates & Forecast, by Region, 2020-2027

7.3.2. Market Estimates & Forecast, by Country, 2020-2027

7.4. Neuromodulation

7.4.1. Market Estimates & Forecast, by Region, 2020-2027

7.4.2. Market Estimates & Forecast, by Country, 2020-2027

7.5. Others

8. GLOBAL MIGRAINE DRUGS MARKET, BY DRUG CLASS

8.1. Overview

8.2. Beta Blockers

8.2.1. Market Estimates & Forecast, by Region, 2020-2027

8.2.2. Market Estimates & Forecast, by Country, 2020-2027

8.3. Angiotensin Blockers

8.3.1. Market Estimates & Forecast, by Region, 2020-2027

8.3.2. Market Estimates & Forecast, by Country, 2020-2027

8.4. Tricyclics

8.4.1. Market Estimates & Forecast, by Region, 2020-2027

8.4.2. Market Estimates & Forecast, by Country, 2020-2027

8.5. Anticonvulsants

8.5.1. Market Estimates & Forecast, by Region, 2020-2027

8.5.2. Market Estimates & Forecast, by Country, 2020-2027

8.6. Triptans

8.6.1. Market Estimates & Forecast, by Region, 2020-2027

8.6.2. Market Estimates & Forecast, by Country, 2020-2027

8.7. Others

9. GLOBAL MIGRAINE DRUGS MARKET, BY END USER

9.1. Overview

9.2. Hospitals and Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.3. Retail Pharmacy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.4. Online Pharmacy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.5. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

10. GLOBAL MIGRAINE DRUGS MARKET, BY REGION

10.1. Overview

10.2. Americas

10.2.1. North America

10.2.1.1. US

10.2.1.2. Canada

10.2.2. Latin America

10.3. Europe

10.3.1. Western Europe

10.3.1.1. Germany

10.3.1.2. France

10.3.1.3. UK

10.3.1.4. Italy

10.3.1.5. Spain

10.3.1.6. Rest of Western Europe

10.3.2. Eastern Europe

10.4. Asia-Pacific

10.4.1. China

10.4.2. India

10.4.3. Japan

10.4.4. Australia

10.4.5. South Korea

10.4.6. Rest of Asia-Pacific

10.5. Middle East & Africa

10.5.1. Middle East

10.5.2. Africa

11. COMPETITIVE LANDSCAPE

11.1. Introduction

11.2. Competitive Analysis

12. COMPANY PROFILES

12.1. Allergan Plc

12.1.1. Company Overview

12.1.2. Financial Overview

12.1.3. Product Offered

12.1.4. Key Developments

12.1.5. SWOT Analysis

12.1.6. Key Strategies

12.2. Alder Biopharmaceuticals, Inc.

12.2.1. Company Overview

12.2.2. Financial Overview

12.2.3. Product Offered

12.2.4. Key Developments

12.2.5. SWOT Analysis

12.2.6. Key Strategies

12.3. Pfizer Inc

12.3.1. Company Overview

12.3.2. Financial Overview

12.3.3. Product Offered

12.3.4. Key Developments

12.3.5. SWOT Analysis

12.3.6. Key Strategies

12.4. GlaxoSmithKline Plc

12.4.1. Company Overview

12.4.2. Financial Overview

12.4.3. Product Offered

12.4.4. Key Developments

12.4.5. SWOT Analysis

12.4.6. Key Strategies

12.5. Merck & Co., Inc.

12.5.1. Company Overview

12.5.2. Financial Overview

12.5.3. Product Offered

12.5.4. Key Developments

12.5.5. SWOT Analysis

12.5.6. Key Strategies

12.6. Teva Pharmaceutical Industries Ltd

12.6.1. Company Overview

12.6.2. Financial Overview

12.6.3. Product Offered

12.6.4. Key Developments

12.6.5. SWOT Analysis

12.6.6. Key Strategies

12.7. AstraZeneca Plc

12.7.1. Company Overview

12.7.2. Financial Overview

12.7.3. Product Offered

12.7.4. Key Developments

12.7.5. SWOT Analysis

12.7.6. Key Strategies

12.8. Johnson & Johnson Services, Inc.

12.8.1. Company Overview

12.8.2. Financial Overview

12.8.3. Product Offered

12.8.4. Key Developments

12.8.5. SWOT Analysis

12.8.6. Key Strategies

12.9. Amgen Inc

12.9.1. Company Overview

12.9.2. Financial Overview

12.9.3. Product Offered

12.9.4. Key Developments

12.9.5. SWOT Analysis

12.9.6. Key Strategies

12.10. Eli Lilly and Company

12.10.1. Company Overview

12.10.2. Financial Overview

12.10.3. Product Offered

12.10.4. Key Developments

12.10.5. SWOT Analysis

12.10.6. Key Strategies

12.11. eNeura Inc.

12.11.1. Company Overview

12.11.2. Financial Overview

12.11.3. Product Offered

12.11.4. Key Developments

12.11.5. SWOT Analysis

12.11.6. Key Strategies

12.12. Others

13. APPENDIX

13.1.1. Discussion Blueprint

13.1.2. Related Reports

NOTE:

This table of content is tentative and subject to change as the research progresses.

 In section 10, only the top companies will be profiled. Each company will be profiled based on the Market Overview, Financials, Product Portfolio, Business Strategies, and Recent Developments parameters.

 Please note: The financial details of the company cannot be provided if the information is not available in the public domain and or from reliable sources.


LIST OF TABLES

TABLE 1 GLOBAL MIGRAINE DRUGS MARKET SYNOPSIS, 2020-2027

TABLE 2 GLOBAL MIGRAINE DRUGS MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)

TABLE 3 GLOBAL MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 4 GLOBAL MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 5 GLOBAL MIGRAINE DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 6 GLOBAL MIGRAINE DRUGS MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 7 NORTH AMERICA: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 8 NORTH AMERICA: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 9 NORTH AMERICA MIGRAINE DRUGS MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 10 US: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 11 US: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 12 US: MIGRAINE DRUGS MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 13 CANADA: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 14 CANADA: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 15 CANADA: MIGRAINE DRUGS MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 16 LATIN AMERICA: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 17 LATIN AMERICA: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 18 LATIN AMERICA: MIGRAINE DRUGS MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 19 EUROPE: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 20 EUROPE: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 21 EUROPE: MIGRAINE DRUGS MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 22 WESTERN EUROPE: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 23 WESTERN EUROPE: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 24 WESTERN EUROPE: MIGRAINE DRUGS MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 25 EASTERN EUROPE: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 26 EASTERN EUROPE: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 27 EASTERN EUROPE: MIGRAINE DRUGS MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 28 ASIA-PACIFIC: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 29 ASIA-PACIFIC: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 30 ASIA-PACIFIC: MIGRAINE DRUGS MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA: MIGRAINE DRUGS MARKET, BY END USER, 2020-2027(USD MILLION)


LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL MIGRAINE DRUGS MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL MIGRAINE DRUGS MARKET

FIGURE 4 GLOBAL MIGRAINE DRUGS MARKET SHARE, BY TREATMENT TYPE, 2020 (%)

FIGURE 5 GLOBAL MIGRAINE DRUGS MARKET SHARE, BY DRUG CLASS, 2020 (%)

FIGURE 6 GLOBAL MIGRAINE DRUGS MARKET SHARE, BY END USER, 2020(%)

FIGURE 7 GLOBAL MIGRAINE DRUGS MARKET SHARE, BY REGION, 2020 (%)

FIGURE 8 AMERICAS: MIGRAINE DRUGS MARKET SHARE BY REGION, 2020 (%)

FIGURE 9 NORTH AMERICA: MIGRAINE DRUGS MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 10 EUROPE: MIGRAINE DRUGS MARKET SHARE, BY REGION, 2020 (%)

FIGURE 11 WESTERN EUROPE: MIGRAINE DRUGS MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 12 ASIA-PACIFIC: MIGRAINE DRUGS MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 13 MIDDLE EAST & AFRICA: MIGRAINE DRUGS MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 14 GLOBAL MIGRAINE DRUGS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 15 ALLERGAN PLC.: KEY FINANCIALS

FIGURE 16 ALLERGAN PLC: SEGMENTAL REVENUE

FIGURE 17 ALLERGAN PLC: REGIONAL REVENUE

FIGURE 18 PFIZER INC.: KEY FINANCIALS

FIGURE 19 PFIZER INC.: SEGMENTAL REVENUE

FIGURE 20 PFIZER INC.: REGIONAL REVENUE

FIGURE 21 GLAXOSMITHKLINE PLC: KEY FINANCIALS

FIGURE 22 GLAXOSMITHKLINE PLC: SEGMENTAL REVENUE

FIGURE 23 GLAXOSMITHKLINE PLC: REGIONAL REVENUE

FIGURE 24 MERCK & CO., INC. KEY FINANCIALS

FIGURE 25 MERCK & CO., INC.: SEGMENTAL REVENUE

FIGURE 26 MERCK & CO., INC.: REGIONAL REVENUE

FIGURE 27 TEVA PHARMACEUTICALS INDUSTRIES LTD: KEY FINANCIALS

FIGURE 28 TEVA PHARMACEUTICALS INDUSTRIES LTD: SEGMENTAL REVENUE

FIGURE 29 TEVA PHARMACEUTICALS INDUSTRIES LTD: REGIONAL REVENUE

FIGURE 30 ASTRAZENECA PLC: KEY FINANCIALS

FIGURE 31 ASTRAZENECA PLC: SEGMENTAL REVENUE

FIGURE 32 ASTRAZENECA PLC: REGIONAL REVENUE

FIGURE 33 JOHNSON & JOHNSON SERVICES, INC.: KEY FINANCIALS

FIGURE 34 JOHNSON & JOHNSON SERVICES, INC.: SEGMENTAL REVENUE

FIGURE 35 JOHNSON & JOHNSON SERVICES, INC.: REGIONAL REVENUE

FIGURE 36 AMGEN INC: KEY FINANCIALS

FIGURE 37 AMGEN INC: SEGMENTAL REVENUE

FIGURE 38 AMGEN INC: REGIONAL REVENUE

FIGURE 39 ELI LILLY AND COMPANY: KEY FINANCIALS

FIGURE 40 ELI LILLY AND COMPANYSEGMENTAL REVENUE

FIGURE 41 ELI LILLY AND COMPANY: REGIONAL REVENUE

FIGURE 42 ENERA INC: KEY FINANCIALS

FIGURE 43 ENERA INC: SEGMENTAL REVENUE

FIGURE 44 ENERA INC: REGIONAL REVENUE



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.

Migraine Drugs Market